Healthcare


 Momentum Builds in ASX Healthcare as Stocks Soar and IPOs Revive Market Activity

Momentum Builds in ASX Healthcare as Stocks Soar and IPOs Revive Market Activity

November 29, 2024 06:27 PM AEDT| By Team Kalkine Media

Highlights,Imricor IMR rises 30% after trial update and licensing agreement.,Vitrafy VFY and Renerve RNV make successful ASX debuts.,ASX healthcare sector outperforms broader market with 4.3% gain.,The Australian healthcare sector has shown signs of...

 MedAdvisor Limited’s New Share Issuance Reaches ASX

MedAdvisor Limited’s New Share Issuance Reaches ASX

November 29, 2024 04:03 PM AEDT| By Team Kalkine Media

Highlights:,MedAdvisor Limited (ASX:MDR) issues 100,000 fully paid ordinary shares as part of an employee incentive scheme.,The new shares will be quoted on the Australian Securities Exchange (ASX) under the code MDR.,This initiative is aimed at moti...

 Small-Cap Highlights: European Lithium Leads the Pack with Notable Gains

Small-Cap Highlights: European Lithium Leads the Pack with Notable Gains

November 29, 2024 03:23 PM AEDT| By Team Kalkine Media

Highlights,Orthocell,gains momentum with its international expansion and distribution deal.,European Lithium surges following a strategic project acquisition.,Multiple small caps,showcase,strong performance,across diverse sectors.,The small-cap secto...

 Algorae Pharma’s AI-Driven Cardiovascular Drug AI-168 Shows Promising Pre-Clinical Results

Algorae Pharma’s AI-Driven Cardiovascular Drug AI-168 Shows Promising Pre-Clinical Results

November 29, 2024 02:30 PM AEDT| By Team Kalkine Media

Highlights,AI-168 shows,cardioprotection,and outperforms beta blockers in studies,.,International patent filed for AI-168, aiming for global market coverage,.,Expanding therapeutic pipeline with AI-generated drug targets,.,Algorae Pharmaceuticals (AS...

 Orthocell's Path to Growth: Record Revenue and Global Expansion Plans

Orthocell's Path to Growth: Record Revenue and Global Expansion Plans

November 29, 2024 01:59 PM AEDT| By Team Kalkine Media

Highlights,Orthocell,(OCC) reports a 30% annual revenue growth with strong product performance,.,Remplir,™ poised for launch in the US, targeting the,$1.6 billion,nerve repair market,.,Robust financial health with zero debt and strategic global expan...

 Tryptamine (ASX:TYP) Completes Psilocin Study in Obesity

Tryptamine (ASX:TYP) Completes Psilocin Study in Obesity

November 29, 2024 12:45 PM AEDT| By Team Kalkine Media

Highlights,Tryptamine Therapeutics concludes Phase 1b study of TRP-8803 in obese participants,.,Study provides insights for Phase 2 development with a focus on dose optimization,.,Final results,anticipated,to guide future trials addressing diverse he...

 Pacific Smiles Group Revamps Board Amid Genesis Bidco's Leadership Transition

Pacific Smiles Group Revamps Board Amid Genesis Bidco's Leadership Transition

November 29, 2024 11:54 AM AEDT| By Team Kalkine Media

Highlights,Pacific Smiles Group announces significant board restructuring,.,Genesis Bidco holds majority voting power and extends acquisition offer,.,Leadership changes,set,for December, with new appointees from Genesis Bidco,.,Pacific Smiles Group (...

 Morningstar Ups Pro Medicus Valuation After Major Contract Win

Morningstar Ups Pro Medicus Valuation After Major Contract Win

November 29, 2024 11:32 AM AEDT| By Team Kalkine Media

Highlights,Valuation Boost:,Morningstar raises Pro Medicus' fair value estimate by 8% to AU$43 per share.,Revenue Growth:,FY26 revenue forecast increased to AU$275 million, reflecting a key Trinity Health contract.,Stock Surge:,Pro Medicus shares hav...

 CSL Share Price Struggles in 2024 but Analysts Predict a Strong Rebound

CSL Share Price Struggles in 2024 but Analysts Predict a Strong Rebound

November 29, 2024 11:20 AM AEDT| By Team Kalkine Media

Highlights,Underperformance in 2024:,CSL shares fell 3% compared to a 10% rise in the ASX 200 index.,Analyst Optimism:,Bell Potter forecasts a 17% upside, targeting a price of $345.00.,Growth Catalysts:,Margin recovery and strong performance from CSL...

 Algorae Pharmaceuticals Appoints Dr. Sarah Siggins to Scientific Advisory Board

Algorae Pharmaceuticals Appoints Dr. Sarah Siggins to Scientific Advisory Board

November 28, 2024 04:07 PM AEDT| By Team Kalkine Media

Highlights,New Appointment:,Dr. Sarah Siggins joins Algorae’s scientific advisory board, bringing 14 years of pharmaceutical expertise.,AI Drug Discovery:,Algorae’s AI platform delivers 24 drug targets for oncology indications, progressing to preclin...

 Strategic Moves Lead to Expansion of Resonance Health’s Global Reach

Strategic Moves Lead to Expansion of Resonance Health’s Global Reach

November 28, 2024 03:57 PM AEDT| By Team Kalkine Media

Highlights:,Resonance Health Ltd (ASX:RHT) has strengthened its position in healthcare technology with its Software-as-a-Medical Device (SaMD) and clinical trial services, utilized in over 400 locations worldwide.,The company’s acquisition of TrialsW...

 Fisher & Paykel Healthcare, Humm, Novonix, and Webjet Shares Experience Setback

Fisher & Paykel Healthcare, Humm, Novonix, and Webjet Shares Experience Setback

November 28, 2024 03:37 PM AEDT| By Team Kalkine Media

Highlights:,Fisher & Paykel Healthcare shares are down 1.5% after its half-year results, with no guidance upgrade for FY 2025.,Humm Group’s share price has dropped 17% following weak guidance and concerns over economic pressures.,Webjet faces a 4% de...

 Pro Medicus Secures Major 10-Year Contract with Trinity Health

Pro Medicus Secures Major 10-Year Contract with Trinity Health

November 28, 2024 03:02 PM AEDT| By Team Kalkine Media

Highlights,Pro Medicus announces a significant $330 million contract with Trinity Health,.,The 10-year deal includes migrating systems to the Visage 7 platform,.,Shares of Pro Medicus saw a strong uptick following the announcement,.,Pro Medicus (ASX:...

 Chimeric Therapeutics Gains Financial Boost with R&D Rebate

Chimeric Therapeutics Gains Financial Boost with R&D Rebate

November 28, 2024 02:57 PM AEDT| By Team Kalkine Media

Highlights,Chimeric Therapeutics (CHM) secures $4.17M R&D tax rebate,.,Funds boost cash reserves, strengthening research potential,.,Focus,remains,on advancing cell therapy for blood cancer,.,Chimeric Therapeutics (ASX:CHM), a biotechnology company s...

 Can Filamon’s Innovative Drug ALPHA-003 Redefine Dementia Treatment?

Can Filamon’s Innovative Drug ALPHA-003 Redefine Dementia Treatment?

November 28, 2024 02:43 PM AEDT| By Team Kalkine Media

Highlights,Filamon’s ALPHA-003 drug discovery offers a more efficient approach to the treatment of dementia.,Unlike current dementia treatments that focus on minimising damage after it has already happened, ALPHA-003 aims to protect brain cells from...

 Lumos Diagnostics Holdings (ASX:LDX): Challenges Amid Declining Revenue Trends

Lumos Diagnostics Holdings (ASX:LDX): Challenges Amid Declining Revenue Trends

November 28, 2024 12:18 PM AEDT| By Team Kalkine Media

Highlights,Lumos Diagnostics shares dropped significantly in the past month,.,The company’s P/S ratio reflects contrasting industry performance,.,Shrinking revenues raise questions about long-term growth prospects,.,Shares of Lumos Diagnostics Holdin...

 Algorae Pharmaceuticals Welcomes Dr. Sarah Siggins to Advisory Board

Algorae Pharmaceuticals Welcomes Dr. Sarah Siggins to Advisory Board

November 28, 2024 11:29 AM AEDT| By Team Kalkine Media

Highlights,Algorae,Pharmaceuticals appoints Dr. Sarah Siggins to its scientific advisory board,.,AI-driven drug discovery platform yields promising oncology targets,.,Strategic focus on innovation and collaboration under Dr. Siggins’ guidance,.,Algor...

 Aroa Biosurgery (ASX:ARX) Shares Gain After Interim Results

Aroa Biosurgery (ASX:ARX) Shares Gain After Interim Results

November 28, 2024 11:00 AM AEDT| By Team Kalkine Media

Highlights,Aroa Biosurgery reports steady revenue growth with industry-leading projections.,Forecasts suggest improved revenue trends but higher projected losses.,Analysts,maintain,a stable outlook with minimal changes to price targets.,Aroa Biosurge...

 Imricor Conducts First Atrial Flutter Ablation Procedure at Swiss Healthcare Facility

Imricor Conducts First Atrial Flutter Ablation Procedure at Swiss Healthcare Facility

November 27, 2024 04:04 PM AEDT| By Team Kalkine Media

Highlights:,Imricor Medical Systems performs its first iCMR ablation procedure at Lausanne University Hospital (CHUV), Switzerland.,CHUV becomes Imricor's first customer site in Switzerland and the third site in the VISABL-AFL clinical trial.,The iCM...

 PYC Therapeutics Advances New Kidney Disease Drug to Human Trials

PYC Therapeutics Advances New Kidney Disease Drug to Human Trials

November 27, 2024 03:50 PM AEDT| By Team Kalkine Media

Highlights:,PYC Therapeutics advances its investigational drug, PYC-003, into human clinical trials for Autosomal Dominant Polycystic Kidney Disease (PKD).,Pre-clinical studies have demonstrated safety, efficacy, and targeted delivery of the drug in...

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.